SAN DIEGO, June 15, 2026 /PRNewswire/ -- Hillhurst Biopharmaceuticals Inc. ("Hillhurst Bio"), a clinical-stage biopharmaceutical company focused on developing novel oral liquid drug products based on known inhaled therapeutics, today announced that the first subject has been dosed in its...
Hence then, the article about hillhurst bio doses first subject in phase 2a clinical trial of hbi 002 a novel therapy for parkinson s disease was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Hillhurst Bio Doses First Subject in Phase 2a Clinical Trial of HBI-002, a Novel Therapy for Parkinson's Disease )
Also on site :
- Russian MOD confirms strikes on Ukrainian military facilities: What we know so far
- KFC leans into boneless chicken, new drinks as chain tries to regain market share
- Pakistani police mistakenly open fire on Australian family, killing child